What’s New in Opportunistic Infections and…Washington DC
Author: Henry A. Masur, MD
Airdate: April 29, 2019 (0 minutes and 0 seconds)
Presented at: Washington, DC
Co-Chair(s): Henry A. Masur, MD, Michael S. Saag, MD
Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.
Please note: Adobe Flash is needed to view webcasts. To download the latest version of Adobe Flash Player, please go to http://get.adobe.com/flashplayer/.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Additional support has been provided by
The International Antiviral Society–USA (IAS–USA) offers no CME credit for this activity.
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
IAS–USA Board of Directors
Constance A. Benson, MD
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. (Updated 05/22//17)
Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)
Judith S. Currier, MD
Dr Currier has received research grants awarded to her institution from Theratechnologies. (Updated 09/25/17)
Carlos del Rio, MD
Dr del Rio has served as a consultant for InnaVirVax. (Updated 01/17/17)
Roy M. Gulick, MD, MPH
Dr Gulick has no relevant financial affiliations to disclose. (Updated 10/16/17)
Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 12/18/17)
Jeanne M. Marrazzo, MD, MPH
Dr Marrazzo currently serves on data and safety monitoring board for Gilead Science, Inc. (Updated 08/11/17)
Douglas D. Richman, MD
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 12/18/17)
Michael S. Saag, MD
Dr Saag has received research grants or has served as a scientific advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, Proteus, and ViiV Healthcare. (Updated 11/29/17)
Robert T. Schooley, MD
Dr Schooley serves as a consultant to CytoDyn and Antiva Biosciences. He is a stockholder of Antiva Biosciences and has stock options from CytoDyn. He serves as a Scientific Advisory Board Member (honoraria remitted to the University of California) for Gilead Sciences, Inc, and LabCorps. (Updated 05/04/17)
Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 02/24/17)
Course Faculty and Staff:
IAS–USA CME Staff
Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).